Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation
Pacing and Clinical Electrophysiology · 2024
DOI: 10.1111/pace.15083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pacing and Clinical Electrophysiology, 2024. Verfasst von Shuyu Jin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Souther…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anti-Arrhythmia Agents, Recurrence, Propafenone. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Department of Science and Technology, Guangdong special funds for science and technology innovation strategy, China.
Abstract (Originalsprache)
Background and objective Treating recurrent atrial arrhythmias after persistent atrial fibrillation (PeAF) ablation is often challenging. This single‐center, prospective study aimed to observe the effectiveness of different combinations of oral antiarrhythmic drugs (AADs) in reverting to sinus rhythm (SR) in patients with recurrent atrial arrhythmias after PeAF ablation.
Methods
Forty‐five patients who experienced recurrent atrial arrhythmias after PeAF ablation were included. Based on their medication regimens, patients were divided into two groups, with the study group being a triple‐drug group (digoxin combined with amiodarone/ propafenone and β‐blocker), and the control group being a non‐triple‐drug group.
Results
The rate of reversion to SR was significantly higher in the study group ( n = 29) than in the control group ( n = 16) at 3 weeks (34.48% vs. 0%, p < 0.01) and 1 month (44.84% vs. 6.25%, p = 0.02) after initiating AADs. No patients with asymptomatic bradycardia were observed in either group.
Conclusions
For patients with recurrent atrial arrhythmias after PeAF ablation, a regimen of low‐dose digoxin combined with amiodarone/propafenone and β‐blocker may effectively improve short‐term reversion rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
- The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
- School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
Förderung
- National Natural Science Foundation of China
- Guangdong Provincial Department of Science and Technology
- Guangdong special funds for science and technology innovation strategy, China
- Zhongnanshan medical foundation of Guangdong Province
Zitieren
APA
Jin, S., Chen, H., Fang, X., Liao, H., Zhan, X., Fu, L., Jiang, J., Ye, X., Liu, H., Chen, Y., Pu, S., Wu, S., Deng, H., Lin, W., & Xue, Y. (2024). Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15083
Vancouver
Jin S, Chen H, Fang X, Liao H, Zhan X, Fu L, et al. Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation. Pacing and Clinical Electrophysiology. 2024. doi:10.1111/pace.15083
BibTeX
@article{Jin2024,
author = {Jin, Shuyu and Chen, Haowei and Fang, Xianhong and Liao, Hongtao and Zhan, Xianzhang and Fu, Lu and Jiang, Junrong and Ye, Xingdong and Liu, Huiyi and Chen, Yanlin and Pu, Sijia and Wu, Shulin and Deng, Hai and Lin, Weidong and Xue, Yumei},
title = {Effectiveness of a Triple Antiarrhythmic Drug Strategy for Arrhythmia Recurrence after Persistent Atrial Fibrillation Ablation},
journal = {Pacing and Clinical Electrophysiology},
year = {2024},
doi = {10.1111/pace.15083}
}
EUVIMED